Oxygen gas
Phase 2Small molecule
Oxygen gas is one of 73 small molecule programs targeting Mortality. It is currently in Phase 2.
4
Indications
11
Total Trials
1
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Mortality
#DrugCompanyPhaseTrials
1Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lovenox
SanofiApproved
Aldactone
PfizerApproved
Coly-Mycin M
PParkedale
Approved
Venofer
AAmerican Regent, Inc.
Approved
Merrem
BB. Braun Medical Inc.
Approved
Zocor
OOrganon and Co
Approved
ZINPLAVA
Merck & Co.Approved
Mounjaro
Eli LillyPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Mortality2 trials
Cardiogenic Shock1 trial
Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock
Completed·—·Phase 3·NCT04990349·60 enrolled
5 more indications
Wound Healing1 trial
Percutaneous Coronary Intervention1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxygen gas. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TThe Hospital for Sick Children